Medicine and Dentistry
Autoimmune Disease
20%
Bortezomib
100%
Case Report
100%
Cyclophosphamide
20%
Cyclosporine
20%
Glucocorticoid
40%
Inpatient
20%
Patient
80%
Plasma Exchange
60%
Relapse
60%
Rituximab
40%
Therapeutic Procedure
40%
Thrombotic Thrombocytopenic Purpura
100%
Von Willebrand Factor Cleaving Proteinase
40%
Pharmacology, Toxicology and Pharmaceutical Science
Autoimmune Disease
20%
Bortezomib
100%
Case Report
100%
Ciclosporin
20%
Cyclophosphamide
20%
Glucocorticoid
40%
Relapse
60%
Rituximab
40%
Thrombotic Thrombocytopenic Purpura
100%
Von Willebrand Factor Cleaving Proteinase
40%
INIS
cyclophosphamide
20%
cyclosporine
20%
glucocorticoids
40%
management
20%
patients
100%
pharmaceuticals
20%
plasma
60%
purpura
100%
refractories
20%
Immunology and Microbiology
Autoimmune Disease
25%
Blood Plasma
75%
Ciclosporin
25%
Cyclophosphamide
25%
Glucocorticoid
50%
Rituximab
50%
Thrombotic Thrombocytopenic Purpura
100%
Keyphrases
Acquired Thrombotic Thrombocytopenic Purpura
50%
Velcade
25%
Neuroscience
Von Willebrand Factor Cleaving Proteinase
50%